You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)

Article Text

Article menu

Download PDFPDF

Poster Presentation
Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
  1. Julie Brahmer1,
  2. Ani Balmanoukian2,
  3. Sarah Goldberg3,
  4. Sai-Hong Ou4,
  5. Andrew Blake-Haskins5,
  6. Joyson Karakunnel5,
  7. Paul Stockman6,
  8. Naiyer Rizvi7 and
  9. Scott Antonia8
  1. Aff1 grid.21107.350000000121719311Sidney Kimmel Comprehensive Cancer Center at John Hopkins University Baltimore MD USA
  2. Aff2 grid.488730.0The Angeles Clinic and Research Institute Los Angeles CA USA
  3. Aff3 grid.433818.5Yale UniversityYale Cancer Center New Haven CT USA
  4. Aff4 grid.266093.80000000106687243Chao Family Comprehensive Cancer Center Orange CA USA
  5. Aff5 grid.418152.bMedImmune USA
  6. Aff6 grid.417815.e0000000104335842AstraZeneca Pharmaceuticals Macclesfield UK
  7. Aff7 grid.51462.340000000121719952Memorial-Sloan Kettering Cancer Center USA
  8. Aff8 grid.468198.a0000 0000 9891 5233H. Lee Moffit Cancer Center and Research Institute USA

https://doi.org/10.1186/2051-1426-2-S3-P179

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    MEDI4736 is an engineered human IgG1 that blocks PD-L1 binding to PD-1 and allows T-cells to recognize and kill tumor. MEDI4736 has single-agent activity and potential for further increased activity in combination. A comprehensive development programme is underway in NSCLC, as monotherapy and in combination.

    Methods

    NSCLC data from 2 multicentre, open-label Phase I studies are reported. NCT01693562 evaluates safety and efficacy of MEDI4736 administered every 2 or 3 weeks. NCT02000947 evaluates safety and efficacy of MEDI4736 in combination with tremelimumab, a human IgG2 anti-CTLA-4 mAb, at 4-week intervals.

    Results

    NCT01693562: As of May 2014, NSCLC cohort included 155 patients (pts) (median age 65 years [33-85], PS 0/1/unknown [25%/73%/2%], median 3 [0-7] prior treatments). Median follow-up: 6 weeks (range 0-67). Treatment-related adverse events (TRAEs): 29% (Grade [Gr] ≥3: 3%); none led to treatment discontinuation. Most frequent TRAEs: fatigue (7%), nausea (5%), and vomiting (5%). No treatment-related colitis any Gr. No treatment-related Gr 3/4 pneumonitis or dyspnea. 58 pts had ≥12 weeks follow-up: 16% had partial response (as early as 6 weeks), duration of response ranged 5-54+ weeks, disease control rate 35%. PD-L1 positivity appears to enrich for response.

    NCT02000947: As of April, 2014, 12 pts treated at 4 dose-levels (PS 0-1, median 3 [2-5] prior treatments). No DLTs observed in any cohort during DLT observation period. Most frequent TRAEs: -↑amylase, abdominal pain, arthralgia, colitis, diarrhea, epigastric discomfort, fatigue and nausea. TRAEs ≥Gr 3 noted in 3 pts: Gr 3 - ↑AST/ALT & Gr 5 myasthenia (MG) (n = 1), Gr 3 diarrhea/colitis (n = 1), Gr 4 - ↑amylase (n = 1). TRAEs led to discontinuation in two subjects: Gr 5 MG and Gr3 colitis. In 12 response-evaluable pts (Figure 1), tumor shrinkage at 8 weeks: 0/3 pts cohort 1a; 6/9 pts cohorts 2a and 3a/b; disease control: 7/12 pts. Dose-escalation ongoing; total of 6 dose-levels, including cohort 5a (MEDI4736/Treme: 15/10 mg/kg), has been cleared since cut-off.

    Figure 1
    Figure 1

    Red: Cohort1a (MEDI4735/Treme: 3/1); Green: Cohort 2a (MEDI4736/Treme 10/1); Gold: Cohort 3a (MEDI4736/Treme 15/1); Blue: Cohort 3b (MEDI4736/Treme 10/3).

    Conclusions

    Current safety profile and encouraging early antitumor activity (monotherapy and combination) support continued development in NSCLC. Additional monotherapy NSCLC studies: Phase II 'ATLANTIC' (NCT02087423), Phase III 'PACIFIC' following chemo-radiotherapy (NCT02125461), Combination: Phase I + gefitinib (NCT02088112), and Phase Ib + AZD9291 (NCT02143466). Monotherapy and combination: Phase III 'ARCTIC' vs standard-of-care.

    Acknowledgments

    Writing support-Isobel Lever/Ashfield Communications, funding-AstraZeneca

    Trial registration NIH